ImmunityBio touts preclinical data on NK cell therapy boosting product

By The Science Advisory Board staff writers

November 23, 2020 -- ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin (IL)-15 "superagonist," improves interferon-gamma production and killing of tumor cells in vitro and in vivo by CD34+ progenitor-derived natural killer (HPC-NK) cells.

Anktiva is currently being evaluated in late-stage clinical trials in combination with NantKWest's NK cell therapies for multiple indications including metastatic pancreatic cancer, triple negative breast cancer, bladder cancer, and lung cancer.

The preclinical studies were conducted at the Radboud Institute for Molecular Life Sciences in the Netherlands. The studies found that Anktiva induces NK cell proliferation and production, improves serial killing properties of NK cells against leukemia, and increases C-X-C motif chemokine ligand 10 (CXCL10) production and killing of ovarian cancer spheroids (in vivo model). In human ovarian cancer mouse models, Anktiva in combination with human immunoglobulins shows anti-tumor effects.

Anktiva has previously received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Bacillus Calmette-Guerin (BCG)-unresponsive carcinoma in situ non-muscle invasive bladder cancer.

ImmunityBio COVID-19 vaccine shows positive clinical results
ImmunityBio has demonstrated that antigens from its bivalent adenovirus-based vaccine candidate are recognized by SARS-CoV-2 reactive human T cells in...
ImmunityBio, NantKwest launch COVID-19 vaccine trial
ImmunityBio and NantKwest have launched phase I of a clinical trial for a COVID-19 vaccine candidate.
ImmunityBio begins phase I trial for its COVID-19 vaccine candidate
ImmunityBio has been authorized by the U.S. Food and Drug Administration to begin a phase I clinical trial of its hAd5-COVID-19 vaccine candidate.
NantKwest scales up COVID-19 stem cell therapy
NantKwest announced that it received investigational new drug authorization from the U.S. Food and Drug Administration (FDA) to treat patients with acute...

Copyright © 2020 scienceboard.net


Conferences
Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter